Spero Therapeutics (SPRO) Competitors $2.29 +0.08 (+3.62%) Closing price 10/20/2025 04:00 PM EasternExtended Trading$2.30 +0.00 (+0.22%) As of 10/20/2025 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SPRO vs. ORGO, MBX, OCGN, ADCT, FULC, INBX, ATXS, CYRX, SLDB, and ALMSShould you be buying Spero Therapeutics stock or one of its competitors? The main competitors of Spero Therapeutics include Organogenesis (ORGO), MBX Biosciences (MBX), Ocugen (OCGN), ADC Therapeutics (ADCT), Fulcrum Therapeutics (FULC), Inhibrx Biosciences (INBX), Astria Therapeutics (ATXS), CryoPort (CYRX), Solid Biosciences (SLDB), and Alumis (ALMS). These companies are all part of the "pharmaceutical products" industry. Spero Therapeutics vs. Its Competitors Organogenesis MBX Biosciences Ocugen ADC Therapeutics Fulcrum Therapeutics Inhibrx Biosciences Astria Therapeutics CryoPort Solid Biosciences Alumis Organogenesis (NASDAQ:ORGO) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk. Do insiders & institutionals have more ownership in ORGO or SPRO? 49.6% of Organogenesis shares are held by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are held by institutional investors. 33.0% of Organogenesis shares are held by insiders. Comparatively, 5.5% of Spero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media refer more to ORGO or SPRO? In the previous week, Organogenesis and Organogenesis both had 3 articles in the media. Organogenesis' average media sentiment score of -0.36 beat Spero Therapeutics' score of -0.75 indicating that Organogenesis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organogenesis 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Spero Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Is ORGO or SPRO more profitable? Organogenesis has a net margin of -1.92% compared to Spero Therapeutics' net margin of -110.35%. Organogenesis' return on equity of -0.37% beat Spero Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Organogenesis-1.92% -0.37% -0.20% Spero Therapeutics -110.35%-120.27%-55.61% Which has stronger valuation & earnings, ORGO or SPRO? Organogenesis has higher revenue and earnings than Spero Therapeutics. Organogenesis is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrganogenesis$482.04M1.07$860K-$0.14-29.14Spero Therapeutics$47.98M2.69-$68.57M-$0.98-2.34 Which has more volatility & risk, ORGO or SPRO? Organogenesis has a beta of 1.68, indicating that its share price is 68% more volatile than the S&P 500. Comparatively, Spero Therapeutics has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500. Do analysts prefer ORGO or SPRO? Organogenesis presently has a consensus target price of $7.33, indicating a potential upside of 79.74%. Spero Therapeutics has a consensus target price of $5.00, indicating a potential upside of 118.34%. Given Spero Therapeutics' higher probable upside, analysts plainly believe Spero Therapeutics is more favorable than Organogenesis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organogenesis 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25Spero Therapeutics 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17 SummaryOrganogenesis beats Spero Therapeutics on 11 of the 14 factors compared between the two stocks. Get Spero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SPRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRO vs. The Competition Export to ExcelMetricSpero TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$124.37M$3.46B$6.14B$10.56BDividend YieldN/A2.27%5.72%4.84%P/E Ratio-2.3423.3929.4727.34Price / Sales2.69486.24588.64242.12Price / CashN/A45.2825.8230.35Price / Book2.6910.6112.526.69Net Income-$68.57M-$52.56M$3.32B$276.46M7 Day Performance-2.97%3.95%1.81%-0.08%1 Month Performance14.50%16.10%8.80%3.93%1 Year Performance78.91%15.08%64.28%33.89% Spero Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPROSpero Therapeutics3.7345 of 5 stars$2.29+3.6%$5.00+118.3%+78.9%$124.37M$47.98M-2.34150Gap UpORGOOrganogenesis3.7832 of 5 stars$3.95-0.3%$7.33+85.7%+29.1%$502.36M$482.04M-28.21950MBXMBX Biosciences3.2733 of 5 stars$14.50-2.7%$42.80+195.2%N/A$500.89MN/A-3.19N/AInsider TradeOCGNOcugen1.094 of 5 stars$1.60-6.4%$6.00+275.0%+72.3%$499.84M$4.05M-8.0080ADCTADC Therapeutics2.5235 of 5 stars$4.63+4.6%$7.75+67.6%+37.2%$497.25M$70.84M-2.95310Analyst RevisionFULCFulcrum Therapeutics1.3132 of 5 stars$8.75-2.7%$9.60+9.7%+162.7%$486.28M$80M-7.17100Analyst ForecastINBXInhibrx Biosciences1.3698 of 5 stars$34.38+5.9%N/A+138.9%$470.27M$200K-3.25166News CoverageATXSAstria Therapeutics1.941 of 5 stars$8.47+1.9%$29.50+248.3%+6.0%$468.97MN/A-4.2130CYRXCryoPort3.3886 of 5 stars$9.40+1.1%$12.56+33.6%+39.6%$465.62M$228.38M7.071,186News CoverageSLDBSolid Biosciences2.8442 of 5 stars$6.01+0.8%$15.00+149.6%-6.8%$464.10M$8.09M-2.15100Analyst DowngradeALMSAlumis3.4667 of 5 stars$4.61+3.8%$20.17+337.5%-60.4%$462.05MN/A0.00N/ANews Coverage Related Companies and Tools Related Companies Organogenesis Alternatives MBX Biosciences Alternatives Ocugen Alternatives ADC Therapeutics Alternatives Fulcrum Therapeutics Alternatives Inhibrx Biosciences Alternatives Astria Therapeutics Alternatives CryoPort Alternatives Solid Biosciences Alternatives Alumis Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SPRO) was last updated on 10/21/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
